Assessment of immunogenicity and efficacy of a Zika vaccine using modified vaccinia Ankara virus as carriers

Assessment of immunogenicity and efficacy of a Zika vaccine using modified vaccinia Ankara virus as carriers

Zika virus (ZIKV) is an emerging mosquito-borne flavivirus that has spread to more than 70 countries worldwide since 2015. Despite active research, there are currently no licensed vaccines or therapeutics. We have previously reported the development of various adenoviral vectored vaccine candidates...

Полное описание

Библиографические подробности
Главные авторы:	López-Camacho, C, Kim, Y, Abbink, P, Larocca, R, Huiskonen, J, Barouch, D, Reyes-Sandoval, A
Формат:	Journal article
Язык:	English
Опубликовано:	MDPI 2019

Схожие документы

Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers
по: César López-Camacho, и др.
Опубликовано: (2019-11-01)

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.
по: Moorthy, V, и др.
Опубликовано: (2003)

New approaches for improving the immunogenicity of modified vaccinia virus Ankara as a recombinant vaccine vector
по: Alharbi, N
Опубликовано: (2014)

Clinical development of Modified Vaccinia virus Ankara vaccines.
по: Gilbert, S
Опубликовано: (2013)

Clinical development of Modified Vaccinia virus Ankara vaccines
по: Gilbert, S
Опубликовано: (2013)

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
по: McConkey, S, и др.
Опубликовано: (2003)

Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.
по: Rosario, M, и др.
Опубликовано: (2010)

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara.
по: Schneider, J, и др.
Опубликовано: (1998)

Safety and immunogenicity of IMVAMUNE®, a third-generation vaccine based on the modified vaccinia Ankara (MVA) strain
по: L. F. Stovba, и др.
Опубликовано: (2023-04-01)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
по: Olga Vladimirovna Orlova, и др.
Опубликовано: (2022-09-01)

Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara
по: Nereida Jiménez de Oya, и др.
Опубликовано: (2022-03-01)

Immunogenicity and efficacy of Zika virus envelope domain III in DNA, protein, and ChAdOx1 adenoviral-vectored vaccines
по: López-Camacho, C, и др.
Опубликовано: (2020)

Deletion of fifteen open reading frames from modified vaccinia virus Ankara fails to improve immunogenicity
по: Alharbi, N, и др.
Опубликовано: (2015)

Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity.
по: Naif Khalaf Alharbi, и др.
Опубликовано: (2015-01-01)

Immunogenicity and Safety of Modified Vaccinia Ankara (MVA) Vaccine—A Systematic Review and Meta-Analysis of Randomized Controlled Trials
по: Lior Nave, и др.
Опубликовано: (2023-08-01)

Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
по: Kaïdre Bendjama, и др.
Опубликовано: (2017-09-01)

Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles
по: Goepfert P, и др.
Опубликовано: (2012-09-01)

Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial
по: Milligan, I, и др.
Опубликовано: (2016)

Immunogenicity and reactogenicity of novel adenovirus type 26 and modified vaccinia Ankara-vectored Ebola vaccines: A randomized clinical trial
по: Milligan, I, и др.
Опубликовано: (2016)

Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis.
по: Mcshane, H, и др.
Опубликовано: (2001)

Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction.
по: Behboudi, S, и др.
Опубликовано: (2004)

Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines
по: César López-Camacho, и др.
Опубликовано: (2020-06-01)

Reactogenicity and Immunogenicity Against MPXV of the Intradermal Administration of Modified Vaccinia Ankara Compared to the Standard Subcutaneous Route
по: Valentina Mazzotta, и др.
Опубликовано: (2024-12-01)

Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.
по: Goonetilleke, N, и др.
Опубликовано: (2003)

The third generation modified vaccinia Ankara vaccine is effective in preventing the transmission of mpox
по: Mingwang Shen, и др.
Опубликовано: (2024-10-01)

Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations.
по: Gilbert, S, и др.
Опубликовано: (1999)

Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus
по: Juan García-Arriaza, и др.
Опубликовано: (2021-08-01)

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.
по: Jeffrey R Currier, и др.
Опубликовано: (2010-11-01)

Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.
по: Sandhya Vasan, и др.
Опубликовано: (2010-01-01)

Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice.
по: Hanke, T, и др.
Опубликовано: (1998)

Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects.
по: Howles, S, и др.
Опубликовано: (2010)

Improved Host Range Selection for Recombinant Modified Vaccinia Virus Ankara
по: Caroline Staib, и др.
Опубликовано: (2003-04-01)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
по: Volker Sandig, и др.
Опубликовано: (2013-11-01)

Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates
по: Leonie Mayer, и др.
Опубликовано: (2024-11-01)

Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus
по: Flavia Chiuppesi, и др.
Опубликовано: (2024-02-01)

The Efficacy of Disinfection on Modified Vaccinia Ankara and African Swine Fever Virus in Various Forest Soil Types
по: Franziska Tanneberger, и др.
Опубликовано: (2021-10-01)

Ebola virus – prospects for a novel virus-like-particle-expressing modified vaccinia Ankara-based vaccine
по: Harriet L. Robinson, и др.
Опубликовано: (2018-09-01)

Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
по: David A Garber, и др.
Опубликовано: (2009-01-01)

Correction: Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates
по: Leonie Mayer, и др.
Опубликовано: (2024-12-01)

Transient Host Range Selection for Genetic Engineering of Modified Vaccinia Virus Ankara
по: C. Staib, и др.
Опубликовано: (2000-06-01)